Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Dec 1;63(11):1479-1481.
doi: 10.1093/cid/ciw579. Epub 2016 Aug 23.

Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials

Jason Grebely  1 , Gregory J Dore  1 , Stefan Zeuzem  2 , Richard J Aspinall  3 , Raymond Fox  4 , Lingling Han  5 , John McNally  5 , Anu Osinusi  5 , Diana M Brainard  5 , G Mani Subramanian  5 , Macky Natha  5 , Graham R Foster  6 , Alessandra Mangia  7 , Mark Sulkowski  8 , Jordan J Feld  9
Affiliations
Clinical Trial

Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials

Jason Grebely et al. Clin Infect Dis. .

Abstract

In this analysis of the ASTRAL trials (non-opioid substitution therapy [OST], n = 984; OST, n = 51) evaluating the once-daily, pan-genotypic regimen of sofosbuvir/velpatasvir for hepatitis C virus infection, OST did not impact completion, adherence, sustained virologic response (SVR12), or safety. SVR12 was 96% (95% confidence interval, 87%, >99%) in those receiving OST.

Keywords: HCV; OST; PWID; sofosbuvir; velpatasvir.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Sustained virologic response (SVR) in patients with chronic hepatitis C virus genotypes 1–4 receiving and not receiving opioid substitution therapy (OST) and sofosbuvir/velpatasvir in the ASTRAL 1–3 studies.
See this image and copyright information in PMC

References

    1. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013; 10:553–62. - PubMed
    1. Feld JJ, Jacobson IM, Hezode C et al. . Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 2015; 373:2599–607. - PubMed
    1. Foster GR, Afdhal N, Roberts SK et al. . Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015; 373:2608–17. - PubMed
    1. AASLD /IDSA. Recommendations for testing, managing, and treating hepatitis C. In; 2015. Available at: www.hcvguidelines.org/. Accessed 1 September 2016. - PubMed
    1. Grebely J, Robaeys G, Bruggmann P et al. . Recommendations for the management of hepatitis C virus infection among people who inject drugs. Int J Drug Policy 2015; 26:1028–38. - PMC - PubMed

Publication types

MeSH terms